Role of Phage Therapy in COVID-19 Infection: Future Prospects by Singh, Amresh Kumar et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors




the world’s leading publisher of
Open Access books







Role of Phage Therapy in  
COVID-19 Infection: Future 
Prospects
Amresh Kumar Singh, Vivek Gaur and Ankur Kumar
Abstract
The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 
was first reported in Wuhan City, China, in 2019. After that, the outbreak has grown 
into a global pandemic and definite treatment for the disease, termed coronavirus 
disease 2019 (COVID-19), is currently unavailable. The slow translational progress in 
the field of research suggests that a large number of studies are urgently required for 
targeted therapy. In this context, this hypothesis explores the role of bacteriophages 
on SARS-CoV-2, especially concerning phage therapy (PT). Several studies have 
confirmed that in addition to their antibacterial abilities, phages also show antiviral 
properties. It has also been shown that PT is effective for building immunity against 
viral pathogens by reducing the activation of NF kappa B; additionally, phages 
produce the antiviral protein phagicin. Phages can also induce antiviral immunity 
by upregulating expression of defensin 2. Phages may protect eukaryotic cells by 
competing with viral adsorption and viral penetration of cells, virus mediated 
cell apoptosis as well as replication. Moreover, by inhibiting activation of NF-κB 
and ROS production, phages can down regulate excessive inflammatory reactions 
relevant in clinical course of COVID-19. In this chapter, we hypothesize that the PT 
may play a therapeutic role in the treatment of COVID-19.
Keywords: phage therapy, phage display, NF-κB, bacteriophage, SARS-CoV-2, 
COVID-19
1. Introduction
Phages are infections caused by bacterial viruses and they are the most bountiful 
elements on the Earth [1], due to the introduction of antibiotics their application 
in clinical practice was immediately overcome in Western countries [2]. Patients 
with antibiotic-resistant infections are traveling from different spots to Georgia 
and Poland for phage treatments [3]. Despite all the success cases of patients, phage 
therapy is still faces significant obstacles, particularly administrative issues. In 
European countries and United States several on-going efforts are being led for the 
acceptance of phage therapy [4]. In this chapter, we will first discuss the early and 
current state of phage therapy, address the major challenges faced by phage therapy 
treatment in Covid-19 infection and the future prospects in this field [5].
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1.1 Early studies of phage therapy (PT)
The efficacy of the phage treatment was confirmed when three patients having 
the same infection dysentery treated with one dose of the anti dysentery phages 
and recovered within 24 hours of treatment but his study was not published [1]. 
However, treatment of infectious diseases of humans reported in 1921 by Richard 
Bruynoghe and Joseph Maisin, who used bacteriophages to treat staphylococcal skin 
disease [6]. In addition, d’Herelle used various phage preparations in India to treat 
thousands of peoples suffering with cholera and bubonic plague [7].
Phages mediate immune regulatory and immunotherapeutic trials that are 
significant in balancing the immunological homeostasis in human [8]. It was 
suggested that the viability of PT in autoimmune diseases and it can also be used 
to for the treatment of infection caused by SARS-CoV-2virus [9]. To determine the 
infection in mass population, a single sewage test is enough to examine the whole 
population has been infected or not because RNA of SARS-CoV-2 remains stable 
with the capsid [10]. However, it has been found from accessible information that 
although the concentration of the virus in sewage water is high but the transmission 
risk via this route is very low. This information can play a major role in managing 
COVID-19 [11].
Phage display technique of producing antibodies was developed for MERS-CoV 
and effectively applied in light of the fact that bacteriophages have the potential 
to produce recombinant antibodies (Ab) rapidly [12]. Another Yin-Yang biopan-
ning technique features the chance of utilizing crude antigens for the isolation 
of monoclonal Ab by phage display method [13]. Before using these expensive 
techniques, production of artificial Ab was primarily done by using animals but it 
is a slow process and less cost effective than using bacteriophage display techniques 
[14]. Bacteriophage could be used to decrease the mortality rate due to Covid-19 
pandemic, and for the production of artificial Ab against SARS-CoV-2 in the early 
stages of infection [15, 16].
2. Interactions between phages and the immune system
It is well known that the immune system plays an important role in phage 
clearance from animal and human bodies [17]. Components of the mono nuclear 
phagocyte system (MPS) in the spleen and liver are major sites of phage accumula-
tion. The MPS has been credited for the quick expulsion of administered wild-type 
phage λ from the human circulatory system [18]. In addition, these phages can 
directly interact with immune cells by either interacting with cell surface molecules 
or receptors or through phage transcytosis [19]. Besides the take-up of phages, by 
Ag presenting cells (APC; e.g., dendritic cells) prompts the activation of B-cells and 
the exhibition of specific Ab against the phage as shown in Figure 1 [20].
3. Mode of action
In spite of the huge number of publications on phage therapy, there are only 
few reports in which the pharmacokinetics of therapeutic phage preparations 
is depicted [21]. Phages get into the circulatory system of experimental animals 
(after giving a single dose orally) within 2 to 4 h and they reached into the 
internal organs within 10 hours and can remains in the human body up to several 
days [22]. In any case extra exploration is required in order to obtain rigorous 
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pharmacological information concerning lytic phages, including full-scale 
toxicological research. [23]. However, after few years studies reveal that not all 
phages replicate correspondingly and that there are significant differences in 
the replication cycles of lytic and lysogenic phages as shown in Figure 2 [11]. 
Moreover, it is possible that numerous therapeutic phages act through a com-
mon path; however, it may also possible that some therapeutic phages have some 
distinctive unidentified genes or some unknown mechanisms responsible for 
lysis of their target bacteria [24]. In a study conducted by Sulakvelidze et al.  
More interpretation of these and common mechanisms is likely to produce 
Figure 1. 
Interaction of bacteriophage with mammalian immune cells (Belleghem et al. [20]).
Figure 2. 




Schematic diagram indicating areas where phage therapy had been applied clinically (Ng et al. [33]).
information useful for genetically engineering which was helpful in effective 
therapeutic phage preparations for the treatment of Coronavirus [7].
3.1 How can ms2 bacteriophage help to fight against coronavirus?
MS2 Bacteriophage is contemplating as a control to study molecular biology 
processes. It includes viral RNA replication, translation method, and physiology 
of infected cells. MS2 RNA coding for viral polypeptides includes protein A, coat 
protein, and RNA replicase complex. The structure of the MS2 virus comprises of 
Protein A and coat protein makeup.MS2 Bacteriophage can be used as an internal 
control in RT-PCR testing for COVID-19 to prevent false negative results and to 
verify the efficacy of the sample preparation and absence of inhibitors in the PCR 
reaction. [25]
4. Phage therapy in humans
Human phage therapy has been practiced in France since 1919, d’Hérelle 
carried out very extensive studies especially in fowl typhoid and in cholera. In 
1921 Bruynoghe and Maisin, Belgium reported that injecting phages target-
ing Staphylococcus near the base of cutaneous boils (furuncles and carbuncles), 
prompted improvement within 48 hours includes reduction in irritability [26–28].
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A study conducted in by G. Lang revealed the utilization of bacteriophage in 
seven patients with chronic orthopedic infections with antibiotic resistant organ-
isms. He was able to fix two out of seven cases of hip prostheses (after removal of 
the prostheses) infected by Gram-negative bacteria, one case of tibial osteomyelitis 
because of the infection caused byProteus spp., Staphylococcus aureus and Klebsiella 
spp.; one instance of septic arthritis of the knee caused due to Enterobacter spp. and 
Staphylococcus aureus, one case of septic non-union of the femur due to pan-drug 
resistant (PDR) Providencia [29, 30]. Henri de Montclos expressed that phage appear 
to be safe for human cells though potentially there could be problems associ-
ated with their modes of preparation. He also stated about propagation on media 
produced from animal tissues [31].
The Pasteur Institute stopped making therapeutic cocktails of phages but few 
French physicians have continued to use phages therapeutically and obtaining 
their phages from Russia or Georgia. Infections through Staphylococcus appear to 
be the most common target which was treated by phages. In 2011 Abedon et al. 
reported successful phage therapy in two patients from France and Australia who 
had strong history of antibiotics treatment and other therapies [32]. There are many 
body places, where phage therapy have been applied and investigated as shown in 
Figure 3 [33].
5. A future for phages
The research on phages and their possible antiviral properties are fundamental 
and should be approved by meticulous in-vitro and in-vivo studies. If lab research 
shows some promising results, then it could be possible to have clinical research and 
randomized stage from one to three human trials to prove their therapeutic utility. 
Phage therapy may likewise hold promise as a treatment for SARS-CoV-2 [11].
The bacterial growth rate might potentially be diminished by the aerosol use 
of bacteriophages that prey on the original species of bacteria responsible to cause 
respiratory failures [34]. This can occur in a self-administrative manner, similar 
to prey–predator regulation in ecosystem. The remarkable development of the 
bacteriophage population should allow for a fast clearance, particularly in situations 
where the bacterial population has already grown significantly [35].
In a study conducted by Prazak et al. in 2020, they found the evidences that pneu-
monia can be treated by nebulized bacteriophages. Target bacteria that commonly 
cause respiratory problems and selection of bacteriophages can be quickly identified 
through screening method and by group of experts. Prophylactically administered 
bacteriophages decreased lung bacterial burdens and improved endurance of 
antibiotic resistant S. aureus infected animals with regards to ventilator-associated 
pneumonia [36]. It should be ensured to have the right selection of bacteriophages 
that target both the optimal bacteria and should be most effective against bacterial 
population growth. The bacteriophages should not interfere with the patient’s innate 
or adaptive immunity. It is also very necessary to rule out that patient does not have 
antibodies toward bacteriophages used, nor develops any antibodies toward bac-
teriophages to clear off the bacteriophage earlier than to SARS-CoV-2. If required, 
quantitative microbiome sequencing can be used potentially in phage therapy [16].
Another obstruction could be a risk of particular species of micro-organism 
which may develop resistance to the bacteriophage [37]. However, this would be 
significantly less serious than the drug resistance problem as it would just reduce 
the efficacy of that one bacteriophage and there is the chance of the bacteriophage 
also adapting to overcome any resistance to it. They are much specific to one species 
of bacteria and there is very minor possibility of the bacteriophage damaging any 
Bacteriophages
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beneficial bacteria but still these things need to be verified through clinical trials. 
It has to be noted that decrease bacterial growth in critical time of illness allows the 
patient more time to recover from the SAR-CoV-2 infection [16].
6. Development of a phage display panning strategy
The phage display technology is based on the integration of a gene encoding 
a peptide or a protein fused with the phage coat proteins was first described by 
George Smith in 1985 [38]. The most broadly used coat proteins for display are the 
PVIII and PIII proteins; however, other coat proteins likewise been utilized for dis-
play. As a result of its high copy number (~2700 copies), the PVIII protein has been 
just utilized for the display of small peptides due to conformational issues hamper-
ing capsid formation. The PIII system, on the other hand, with its low copy number 
(5 copies), allows the display of larger molecules such as recombinant antibodies 
[12]. The first phage display system as shown in Figure 4 displaying antibodies was 
explained by Mc Cafferty et al. in 1990. They effectively showed variable regions of 
antibody on phages by using immunoglobulin variable genes of hybridomas and B 
cells [39]. After its innovation, phage display technology has been extensively used 
for the research and discovery of antibodies or peptides against a large variety of 
antigens in many fields of application such as toxicology, drug discovery, immuni-
zation, epitope mapping and virus or toxin neutralization by using phage peptide 
and antibody libraries. Phage display technology has been intensively used for the 
production of neutralizing antibodies as shown in Table 1 [40].
Various antibody libraries of different methodologies and strategies have been 
screened against SARS-CoV-2 spike protein and its receptor binding domain (RBD). 
Few studies have focused on screening previously developed libraries against SARS-
CoV and MERS-CoV and finding cross-reactive antibodies. Others have performed 
screenings against semisynthetic or synthetic antibody libraries [41]. Phage 
displayed single-domain antibody was previously developed from llama, which 
simultaneously neutralizes the S antigen of SARS-CoV and also help in the neutral-
ization of S antigen of the pseudotyped virus SARS-CoV-2 as a bivalent human IgG 
Fc-fusion protein. A selected antibody has high affinity to RBD, for this a library 
Figure 4. 
Schematic presentation of phage display systems (Bazan et al. [12]).
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constructed and screened against the RBD domain of the SARS-CoV-2 spike antigen 
known as phage displayed synthetic human Fab library [42].
ELISA and pseudo typed virus neutralization assay. A phage-displayed single-
domain antibody library has been developed by grafting naive CDR regions into the 
framework region of an allele in the human antibody heavy chain variable region. 
They made affinity selection against the RBD domain and the S1 subunit of SARS-
CoV-2 and chose several neutralizing antibodies, including a “cryptic” epitope 
located in the spike’s trimeric interface.A site directed screening was performed in 
a naive human scFv antibody library and domain antibody library by phage display 
against SARS-CoV-2 RBD. After several rounds of screening, they obtained 9 
enriched clones from the domain antibody library and a single clone from the scFv 
antibody library. The scFv clone was reformatted into a human IgG1 antibody, while 
the domain antibody clones were fused with human Fc tag. A potential neutralizing 
effect of these recombinant antibody structures revealed with pseudotyped virus 
neutralization assay [15].
The future of phage therapy is not necessarily to replace current therapies, 
rather there is potential for clinical applications to enhance and provide another 
treatment for infections. Research in this area is likely to grow at an exponential 
rate. However, the full potential of phage therapy can only be accomplished when 
there is transparency and an eagerness to share knowledge as well as resources. 
Preferably, phage libraries should be freely accessible through a network of col-
laboration, information on preparation and delivery methods for phages implied 
for clinical usage should be well documented. Phage articulation and delivery are 
also critical considerations in order to direct activity to targeted areas and maxi-
mize efficacy. In fact, use of phage therapy already appears to be as of now gives 
off an impression of being composed in different nations, and by major public 
health institutes such as Therapeutic Goods Administration (TGA) (Australia), 
Food and Drug Authority (FDA) (United States of America) and the European 
Medicines Agency (EMA) (Europe). Importantly, a universal code of ethics should 
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Table 1. 
Phage display strategies for neutralizing antibody development (BalcioĞlu et al. [15]).
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be established and regulatory bodies reach a consensus on the exchange of informa-
tion, usage of phages as treatment and reporting of treatment outcomes. Due to 
the critical nature of the rise of multiple drug resistance (MDR), expanding the 
urgency for phage therapy to be implemented as standard consideration, alternative 
therapies to be translated into clinical applications need to be expedited. A con-
certed effort with both national and international partners could see phage therapy 
being translated into standard care in the next 5 years [33].
7. Phages as potential inducers of antiviral immunity
There are also data suggesting that phages may drive antiviral immunity by induc-
ing antiviral cytokines, for example, IFN-α and IL-12. An experimental study that 
phage RNA may induce IFN-α in human granulocytes [43]. Recently, Sweere et al. 
demonstrated that Pf phages (and phage RNA) endocytosed by leukocytes trigger 
TLR3-dependent pattern recognition receptors and inhibit TNF-driving type I IFN 
production [44]. The phage-dependent virucidal sign in the lungs could be happen 
in the phage has capable enough to penetrate the body organ through various routes; 
therefore phage therapy has been applied successfully in respiratory tract. Intriguingly 
a fine respiratory microbiome including bacteriophages, during the event of viral 
pathogens even such as Corona virus is also related with quite low percentage of 
phages. Recent data indicate that Lactobacillus, E. coli and Bacteroides phages and phage 
DNA may stimulate IFN-γ production via TLR9 activation. IFN-γ is another potent 
antiviral cytokine. Although, the increase TNF level might cause significant risk of 
virus replication. Hence, a therapeutic agent could regulate TNF production to keep the 
values at normal level for patient could be appreciated. Pre-clinical studies suggest that 
viral pneumonia may be cured by anti-TNF therapy. As increased levels of TNF are in 
blood samples and tissue from patients with COVID-19 may be inhibit TNF production 
through phage, which is confirmed by other author’s previous reports that showed 
phage may down regulate TNF-α level in serum and lungs of mice with experimental 
acute pneumonia. Interestingly, clinical phage therapy may reduce TNF production 
when its pre-treatment level is high and increase it in low responders [45, 46].
These informations might be considered as a relevant argument for phages as 
a potential agent that could help to decrease TNF levels, allowing for appropriate 
antiviral immune responses in COVID-19 while reducing the risks of excessive 
immunosuppression. Different Phages may also interact with TLR [47]. TLR2 is 
involved in antiviral responses as a result of recognition of the repeating protein 
subunit patterns common to many viral capsids. [Induction of Antiviral Immune 
Response through Recognition of the Repeating Subunit Pattern of Viral Capsid Is 
Toll-Like Receptor 2 Dependent]. Other antiviral effects could be mediated by the 
A5/80 Staphylococcal phage through its ability to increase the expression of the 
IL-2 gene. IL-2 drives NK cell activity, which is important in defines against viral 
infections [47]. Phage can also induce antiviral immunity by up regulating expres-
sion of defense in IL-2, and recently shown that the T4 phage may induce a marked 
up regulation of gene coding for hBD2, a multifunctional peptide expressed mainly 
in epithelial cells with antiviral activity. Virus replication disrupt by the peptide 
through the binding of the virus by hBD2, decrease viral replication and modula-
tion of signaling pathway essential for virucidal effects, even do the recruitment of 
immune cells contributing to antiviral activity leading to down regulation of cyto-
pathic effects in human alveolar and laryngeal epithelial cells [48]. In some experi-
ment studies in mice have revealed a co-relation between beta-defensin expression 
and pulmonary immunity. Moreover, participation of hBD2 in antiviral defenses in 
the respiratory tract has been confirmed in human disorders [49].
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It was advised that phages could be reintroduced for the treatment of not only 
bacterial, but also other infections such as viral and fungal infections (Adv, Epstein–
Barr virus, Aspergillus fumigatus, Candida albicans). It showed that there is evidence 
that proof phage could be comprised in current treatment being studied for re-
purposing in the therapeutic treatment of COVID-19. According to Gorskiet et al. 
phage in COVID-19 could be in an adjunct antiviral therapy, which is quite similar 
to the current trend ofcombined phages with antibacterial treatment in bacterial 
infections. In other way, a standard phage therapy could be considered for the 
treatment of bacterial complications of COVID-19, which occur in >40% of patients 
[45, 50]. Phages may act as shield for eukaryotic cells by competing with surface 
assimilation and viral penetration of cells; virus mediated, programmed cell death 
as well as viral replica. Phages may also arouse antiviral immunity during contrib-
uting to a equal immune response. Moreover, by inhibiting activation of NF-κB 
and ROS production, phages can down regulate extreme inflammatory reactions 
relevant in pathology and clinical course of COVID-19. The data presented in this 
which was judged are often preliminary but suggest that further studies centered 
on the potential of phage therapy as at least an adjunct treatment of COVID-19 are 
warranted. Both general and remote safety of phage therapy was corroborating in 
human viral diseases. Therefore, extensive studies comprising relevant clinical trials 
are needed to prioritize applicability of phage to help fighting against COVID-19 
pandemic [45].
8. Production of industrial phage propagation strains
The development of new page-based resources using traditional methods can be 
an on-going issue that may require hundreds of species to be treated with plasmids, 
active prophages, perhaps other mobile genomic elements. However, given the 
recent breakthroughs in synthetic biology and advances in re-integration with 
genetic engineering methods, this need not be the case. Even a given phage infects 
a particular type of bacterium strain from the affected species depending on the 
bacterial characteristics and the phage [45].
Metabolic compatibility of a bacterium with a phage to support the propagation 
of the phage in an already existing infection appears to be specific to certain species, 
but is sometimes extended to more than one species of bacteria of the same or dif-
ferent genera. Definitions of phage acquisition differentiation encoded by a variety 
of similar species include genes that include phage receptors or their means of inte-
gration and restriction-modification systems associated with the phage. In addition, 
bacteria, encrypt phage defense process but these mechanisms fortify the bacterium 
itself from infection through certain pathogens or through the propagation of 
phage, or induce apoptosis to protect people from the spread of the disease [45].
The distinct indicators of phage determinants are reversible between the strains 
of given species. Bacteria can gain or lose sensitivity to an appropriate phage or the 
ability to support the phage development by mutation-recombination-, or horizontal 
genetically modified changes in their phage orientation or phage defense determi-
nants [51]. There are so many genes which are analogous with phage resistance or 
susceptibility exposure is carried by mobile genetic elements. Key features of Phage 
that are important of a metabolically-compatible host include the interaction of 
phage receptor-binding proteins and receptors on the surface of the bacterial cell, 
alignment of the phage genome with the bacterial restriction-modification mutation 
system, or the ability to prevent bacterial action by bacterial restriction-modification 
systems or by encoding efficient anti-restriction mechanisms. In addition, to 
infect bacteria, phage reproduce effectively, protein-induced phage allows them 
Bacteriophages
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to overcome bacterial phage-resistant strains, such as anti-CRISPR proteins and 
proteins that inhibit the action of Abi systems or toxin-antitoxin (TA) [51, 52].
The structure of each phage and its infectivity for a specific host are determined 
by the genetic makeup of the phage. The only factors determined by phage handling 
are considered to be some epigenetic alterations, which are patterns related to host 
DNA methylation [52]. They have a significant impact on the functioning of new 
host infections by a phage; play a very important role in horizontal gene transfer 
through bacteriophages. Therefore, in addition to the species-specific metabolic 
pathways specific to supporting the efficient propagation of a given phage and 
which should be equipped with surface receptors for this phage attachment, 
envelope structures of cell susceptible to the action of the phage lytic protein, and 
a block-conversion modification system that will allow in this case to infect the 
desired set of phage in clinics [45, 53].
Removal of such strains of genetic determinants of other phage defense mecha-
nisms (e.g., CRISPR/Cas, Abi, or TA loci), if there is a genetic mutation, can extend 
the number of phages it can propagate to its cells to phage infecting the strains of 
the same species and uses the same receptors, but is in capable to overcome the 
suitable defense. The discovery of sensitivity to several specific phages upon the 
abolishment of various bacterial phage defense systems has been demonstrated in a 
number of cases. A good future strategy for finding the therapeutic phage propaga-
tion strains of desired properties may be the construction of a bacterial chassis of 
selected clinically relevant pathogenic species. In synthetic biology, the chassis 
refers to the microorganism that serves as the basis for genetic engineering and to 
support them by providing resources for basic tasks, such as replication, transcrip-
tion, and translation mechanisms [45, 53–55].
The common strains of bacterial chassis that will serve as the basic platforms for 
construction of industrial phage propagation should have genomes reduce their com-
plexity and unnecessary genetic content by the depletion of most of the transposable 
element as well as virulence and phage resistance determinants method called as a 
top-down strategy of the genome reduction process [54]. In addition, they ought to 
be prepared for the introduction or exchange of genomic modules which enable these 
strains to function as microbial cells in the use of selected treatment phage. Methods 
to allow the elimination of mobile genetic elements and other genes are used for 
genetic reshuffling recombineering, oligo-mediated allelic replacement, or genome 
editing using CRISPR/Cas-assisted selection of clones for model bacteria, or even 
on a genomic-wide scale. A repertoire of engineering tools that enhances genomic 
deceptive ability in bacteria other than E. coli uses new and ever-evolving techniques, 
providing ways to classify genomes belong to particular genera represented by prob-
lematic bacterial pathogens, including potential phage propagation strain [45].
The results of studies on micro-organisms that were cured of some or most of the 
reсоmbinоgeniс or mobile genetic elements (including рrорhаges) indicate many more 
benefits. The strain, Escherichia соli K-12 with а genomic reduction by approximately 
15% by the removal of mobile DNА and сryрtiс virulence genes. Due to these changes 
this strain preserved gооd growth рrоfile and рrоtein production as well as the ассurаte 
рrораgаtiоn of reсоmbinаnt genes and plasmids that соuld not be stably рrораgаted in other 
strains [56]. Apart from phage capacity in combating different bacterial infections, 
emerging evidence suggests role of phages in viral infections as well treatment. Many 
viral illnesses do not have specific treatment and same antiviral drugs have been used 
for different viral diseases [57]. Thus, in our орiniоn, the соnstruсtiоn for the рrораgаtiоn 
of therарeutiс рhаges, of сhаss is strains equiррed with сertаin рhаge susceptibility deter-
minants and depleted of рhаge resistance determinants as well as сertаin mobiles genetic 
elements or virulence determinants will not only ensure the safety of therарeutiс рhаge 
рreраrаtiоns, but will also reduce the соst of рhаge production substantially [58].
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This reduction will be а result of:
It helps in reducing the number of strains required for the production of differ-
ent types of рhаges.
No need of evaluating рhаge рreраrаtiоns for the composition (temperate рhаges 
and toxins) of undesired elements.
It helps to increase the fitness and stability of these strains in the commercially 
production of therарeutiс рhаges.
In addition, to single fundamental strain establish for а microbial species саn serve 
as а platform for the enrichment of its genome with several gene саssettes required 
fоr the рrораgаtiоn of several рhаges. Further work to remove additional undesired 
genomic elements from the genomes of these strains is in progress [45, 59].
9. Phage-based vaccines
Phage-based vaccines offer significant potential advantages by building up a 
stage approach with the ability to quickly switch the vaccine in response to muta-
tions in the Coronavirus. Also, vaccines based on phages are self-fulfillment, which 
means they automatically activate and boost immune response, with the ability to 
show multiple antigens. The therapeutic use of phage in humans is well understood 
and has a favorable safety measures. Recent studies recommended the immune 
response to SARS-CoV2 could be transient and need frequent booster vaccinations 
to manage defensive levels of immunity [60, 61].
The possible advantages of phage-based vaccines incorporate flexibility for route 
of administration (mucosal and intramuscular), including a potential oral drop, 
adaptability to virus mutations, quick progression and cost-effectiveness. These 
advantages, along with the known safety profile, offer hope as a potential tool in 
reducing this pandemic. Moreover, countries have the potential to increase produc-
tivity rapidly. Researchers are fully committed to combat the impact of this public 
health crisis [60].
9.1 Benefits of phage-based vaccine over other vaccine technologies
• It offers the phages with excellent safety measurements.
• Quickly adaptation of new vaccines to potential mutations in coronavirus.
• Lower cost of manufacturing in comparison with alternative vaccine 
approaches.
• Self-adjuvanting to provoke immune response
10. Challenges to build phage libraries
The main challenges in treating phage are:
1. Doctors need to know exactly what type of bacteria is causing the  
infection.
2. They must have various specific phages target that strain, easily available, in 
fact from a large phage library that can be tested to find the right phage a cock-
tail that matches the bacteria.
Bacteriophages
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To address latter problem, many pharmaceutical companies are reluctant to 
committed resources to improve treatment and therapy. That is because phage 
treatment is almost 100 years old, making it difficult to patent and raise income to 
allow for the initial cost of development. Lack of regulatory permission to manage 
the treatment of the page is problematic. Phage cocktails need to be customized for 
each patient’s infection and regularly organized as the bacteria mutate and improve 
resistance as shown in Figure 5. Regulatory agencies such as the US Food and Drug 
Administration (FDA) currently do not have the necessary review and approval 
mechanisms to be able to accept your identity and adapt to a greater degree. The 
experimental design that benefits from genomic sequence and mass spectrometry 
will soon meet the need for rapid and accurate microbial identification. A second 
barrier to phage treatment, the need for easily accessible therapeutic phage, could 
ultimately be met to some extent by the U.S Medical Research Centre and differ-
ent groups around the world are presently building phage libraries as shown in 
Table 2 [63].
Looking forward, other technological innovations could help make the phage 
treatment more specific and help with patent issues. For an example, phages can 






XFab1 Xoma Naive Fab 3.1 × 1011
XscFv2 Xoma Naive scFv 3.6 × 1011
HAL9/10 TU-IB (b) Naive scFv 1.5 × 1010
KNU-Fab KNU (c) Naive Fab 3.0 × 1010
pIX V3.0 Janssen Bio Synthetic Fab 3.0 × 1010
HuCAL PLATINUM MorphoSys Synthetic Fab 4.5 × 1010
Ylanthia MorphoSys Synthetic Fab 1.3 × 1011
PHILO Diamond ETH Zurich Synthetic scFv 4.1 × 1010
ALTHEA Gold Libraries GlobalBio/ADL Semisynthetic scFv 2.1 × 1010
Source: Almagro et al. [62]
Table 2. 
Example of Phage display antibody libraries.
Figure 5. 
Phage display method to build library of peptides and proteins variants (source: Almagro et al. [62]).
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resistant micro-organism. Some agencies there may also be eligible for patents on 
separate phage or phage cocktails, making them a viable commercial investment [63].
No matter what the future holds for the treatment of the phages, most experts 
agree that the phage treatment will never completely replace antibiotics. Instead, 
this method can be used in combination with antibiotics, or as a last resort to pro-
tect patients with diseases that have not responded to other treatments. Given the 
alarming increase in the number of life-threatening multidrug- resistant diseases in 
recent years, the need to investigate the potential role of phage and other alternative 
to antibiotic treatments is urgently required [64, 65].
11. Conclusion
The progressing SARS-CoV-2 related COVID-19 pandemic is persistently emerg-
ing worldwide and signifying the greatest spotlight on public health, education, 
travels, and monetary conditions in the current world. As irresistible situations 
have no borders because there is no single specific therapy that may give effective 
responses toward COVID-19. Thus, a worldwide activity intends to make phage 
therapy worldwide overall accessible is required. This obviously requires an active 
joint effort between countries for overcoming logistic and administrative challenges 
and among clinicians and researchers for filling current knowledge gap and encour-
aging advances in the field.
How would it be advisable for us to deal with the current infection prevention 
and control a strategy which also works after the epidemic? How could we react to 
similar contagious diseases in the future? These are open questions which require 
further discussion and research. While phages may have the potential to play a 
role in the current pandemic, it is also very important to understand that there is 
no magic stick for this pandemic. The current situation highlights the urgency for 
adhering to clinical pharmacology, therapeutic, preventative and diagnostics inter-
ventions to optimize COVID-19 therapies. The instant and cell free production of 
synthetic phages, whether designed or not? This had considerable advantages over 
classically produced natural phages. Implementation of the right patient, right drug, 
right dosage, and right timing approach helps to reduce the rate of infection. Finally, 
adaptive designs for COVID-19 will lead to the development of more vigorous infec-
tious disease research infrastructure and funding to help mitigate future pandemics.
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